Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.~* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.~* Clinical lab results within the normal range~Exclusion Criteria:~* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.~* Treatment with systemic immunosuppressive medications or biologics.~* Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CTP-543 4 mg BID (Type: EXPERIMENTAL): Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.
- Cohort 2: CTP-543 8 mg BID (Type: EXPERIMENTAL): Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.
- Cohort 3: CTP-543 12 mg BID (Type: EXPERIMENTAL): Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.
- Combined Placebo (Type: PLACEBO_COMPARATOR): Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).